Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients

Author(s): Fatma El-Gebaly, Sabry Abou-saif, Mahmoud Elkadeem, Amal Helmy, Sherief Abd-Elsalam*, Mohamed Yousef, Reham Abdelkader Elkhouly, Ibrahim Fathi Amer, Taher El-Demerdash.

Journal Name: Current Cancer Drug Targets

Volume 19 , Issue 11 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The expression of programmed cell death ligands on tumor cells has a role in the suppression of antitumor immunity, resulting in tumor immune evasion.

Objective: In this study, we evaluated the prognostic value of the soluble form of programmed death-ligand1 (sPD-L1) in Egyptian hepatocellular carcinoma (HCC) patients.

Methods: This prospective cohort study was performed between November 2016 to November 2018 on 85 individuals (25 HCC patients, 25 HCC with vascular invasion and/or extrahepatic metastasis, 25 patients with liver cirrhosis, 10 healthy controls). The levels of sPD-L1 were determined in all subjects and compared in different groups and stages of cirrhosis and HCC. The association between sPD-L1 levels and overall survival (OS) was assessed.

Results: Significant statistical difference in sPD-L1 was detected between different study groups. The cut-off value for normal sPD-L1 was defined by high sPD-L1 levels determined in a healthy control cohort. It was 2.522 ng/ml. In HCC patients, cut-off value was 7.42 ng/ml (sensitivity 88%, specificity 100%). In HCC with vascular invasion or metastasis, cut–off value was 9.62 ng/ml (sensitivity 88%, specificity 88%). Patients with high serum sPD-L1 or serum bilirubin concentrations had an increased risk of mortality.

Conclusion: High sPD-L1 level could be a possible prognostic indicator for a poor outcome in liver cirrhosis and HCC patients. The predictive value of sPD-L1 levels for a successful anti- PD1/PD-L1 therapy should be investigated in the future.

Keywords: Programmed cell death ligand-1, hepatocellular carcinoma, prognosis, antitumor immunity, tumor, metastasis.

[1]
Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55(2), 74-108.
[http://dx.doi.org/10.3322/canjclin.55.2.74] [PMID: 15761078]
[2]
Ferrone, S.; Whiteside, T.L. Tumor microenvironment and immune escape. Surg. Oncol. Clin. N. Am., 2007, 16(4), 755-774. [viii].
[http://dx.doi.org/10.1016/j.soc.2007.08.004] [PMID: 18022543]
[3]
Carter, L.; Fouser, L.A.; Jussif, J.; Fitz, L.; Deng, B.; Wood, C.R.; Collins, M.; Honjo, T.; Freeman, G.J.; Carreno, B.M. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur. J. Immunol., 2002, 32(3), 634-643.
[http://dx.doi.org/10.1002/1521-4141(200203)32:3<634:AID-IMMU634>3.0.CO;2-9] [PMID: 11857337]
[4]
Kassel, R.; Cruise, M.W.; Iezzoni, J.C.; Taylor, N.A.; Pruett, T.L.; Hahn, Y.S. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology, 2009, 50(5), 1625-1637.
[http://dx.doi.org/10.1002/hep.23173] [PMID: 19739236]
[5]
Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol., 2008, 26, 677-704.
[http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331] [PMID: 18173375]
[6]
Afreen, S.; Dermime, S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematol. Oncol. Stem Cell Ther., 2014, 7(1), 1-17.
[http://dx.doi.org/10.1016/j.hemonc.2013.09.005] [PMID: 24398144]
[7]
Ceeraz, S.; Nowak, E.C.; Noelle, R.J. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol., 2013, 34(11), 556-563.
[http://dx.doi.org/10.1016/j.it.2013.07.003] [PMID: 23954143]
[8]
Dong, H.; Zhu, G.; Tamada, K.; Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med., 1999, 5(12), 1365-1369.
[http://dx.doi.org/10.1038/70932] [PMID: 10581077]
[9]
Sheppard, K.A.; Fitz, L.J.; Lee, J.M.; Benander, C.; George, J.A.; Wooters, J.; Qiu, Y.; Jussif, J.M.; Carter, L.L.; Wood, C.R.; Chaudhary, D. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett., 2004, 574(1-3), 37-41.
[http://dx.doi.org/10.1016/j.febslet.2004.07.083] [PMID: 15358536]
[10]
Ghebeh, H.; Mohammed, S.; Al-Omair, A.; Qattan, A.; Lehe, C.; Al-Qudaihi, G.; Elkum, N.; Alshabanah, M.; Bin Amer, S.; Tulbah, A.; Ajarim, D.; Al-Tweigeri, T.; Dermime, S. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors. Neoplasia, 2006, 8(3), 190-198.
[http://dx.doi.org/10.1593/neo.05733] [PMID: 16611412]
[11]
Jacobs, J.F.; Idema, A.J.; Bol, K.F.; Nierkens, S.; Grauer, O.M.; Wesseling, P.; Grotenhuis, J.A.; Hoogerbrugge, P.M.; de Vries, I.J.; Adema, G.J. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-oncol., 2009, 11(4), 394-402.
[http://dx.doi.org/10.1215/15228517-2008-104] [PMID: 19028999]
[12]
Wu, C.; Zhu, Y.; Jiang, J.; Zhao, J.; Zhang, X.G.; Xu, N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem., 2006, 108(1), 19-24.
[http://dx.doi.org/10.1016/j.acthis.2006.01.003] [PMID: 16530813]
[13]
Iacovelli, R.; Nolè, F.; Verri, E.; Renne, G.; Paglino, C.; Santoni, M.; Cossu Rocca, M.; Giglione, P.; Aurilio, G.; Cullurà, D.; Cascinu, S.; Porta, C. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target. Oncol., 2016, 11(2), 143-148.
[http://dx.doi.org/10.1007/s11523-015-0392-7] [PMID: 26429561]
[14]
Aguiar, P.N., Jr; Santoro, I.L.; Tadokoro, H.; de Lima Lopes, G.; Filardi, B.A.; Oliveira, P.; Mountzios, G.; de Mello, R.A. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis. Immunotherapy, 2016, 8(4), 479-488.
[http://dx.doi.org/10.2217/imt-2015-0002] [PMID: 26973128]
[15]
Yanaba, K.; Hayashi, M.; Yoshihara, Y.; Nakagawa, H. Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis. J. Dermatol., 2016, 43(8), 954-957.
[http://dx.doi.org/10.1111/1346-8138.13339] [PMID: 26945563]
[16]
Shi, B.; Du, X.; Wang, Q.; Chen, Y.; Zhang, X. Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases. Metabolism, 2013, 62(6), 778-785.
[http://dx.doi.org/10.1016/j.metabol.2012.12.005] [PMID: 23398844]
[17]
Abd-Elsalam, S.; Elwan, N.; Soliman, H.; Ziada, D.; Elkhalawany, W.; Salama, M.; Hawash, N.; Arafa, M.; Badawi, R.; Shehata, W.M.; Khalil, H.S.; Elmashad, N. Epidemiology of liver cancer in Nile delta over a decade: A single-center study. South Asian J. Cancer, 2018, 7(1), 24-26.
[PMID: 29600229]
[18]
Ziada, D.H.; El Sadany, S.; Soliman, H.; Abd-Elsalam, S.; Salama, M.; Hawash, N.; Selim, A.; Hamisa, M.; Elsabagh, H.M. Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: A single center study. J. Egypt. Natl. Canc. Inst., 2016, 28(4), 257-262.
[http://dx.doi.org/10.1016/j.jnci.2016.06.001] [PMID: 27378258]
[19]
Sheta, E.; El-Kalla, F.; El-Gharib, M.; Kobtan, A.; Elhendawy, M.; Abd-Elsalam, S.; Mansour, L.; Amer, I. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: A randomized-controlled study. Eur. J. Gastroenterol. Hepatol., 2016, 28(10), 1198-1203.
[http://dx.doi.org/10.1097/MEG.0000000000000688] [PMID: 27362551]
[20]
Negm, O.; Abou Saif, S.; El Gharib, M.; Yousef, M.; Abd-Elsalam, S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol., 2017, 29(3), 317-321.
[http://dx.doi.org/10.1097/MEG.0000000000000790] [PMID: 27893491]
[21]
Elwan, N.; Salem, M.L.; Kobtan, A.; El-Kalla, F.; Mansour, L.; Yousef, M.; Al-Sabbagh, A.; Zidan, A.A.; Abd-Elsalam, S. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients. Immunol. Invest., 2018, 47(2), 169-180.
[http://dx.doi.org/10.1080/08820139.2017.1407787] [PMID: 29182438]
[22]
Abdelfattah, A.A.M.; Rizk, F.; Hawash, N.; Hanafy, A.; El-Kalla, F.; Abd-Elsalam, S. Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver. Int. J. Hyperthermia, 2018, 34(8), 1367-1371.
[http://dx.doi.org/10.1080/02656736.2018.1424946] [PMID: 29308685]
[23]
Watany, M.; Badawi, R.; Elkhalawany, W.; Abd-Elsalam, S. Abd- Elsalam S. Study of Dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J. Clin. Diagn. Res., 2017, 11(2), OC32-OC34.
[PMID: 28384913]
[24]
Huo, T.I. ALBI grade as a new player in hepatocellular carcinoma. J. Chin. Med. Assoc., 2019, 82(1), 1.
[http://dx.doi.org/10.1016/j.jcma.2018.07.001] [PMID: 30839395]
[25]
Gabrielson, A.; Wu, Y.; Wang, H.; Jiang, J.; Kallakury, B.; Gatalica, Z.; Reddy, S.; Kleiner, D.; Fishbein, T.; Johnson, L.; Island, E.; Satoskar, R.; Banovac, F.; Jha, R.; Kachhela, J.; Feng, P.; Zhang, T.; Tesfaye, A.; Prins, P.; Loffredo, C.; Marshall, J.; Weiner, L.; Atkins, M.; He, A.R. Intratumoral CD3 and CD8 T-cell densities associated with relapse free survival in HCC. Cancer Immunol. Res., 2016, 4(5), 419-430.
[http://dx.doi.org/10.1158/2326-6066.CIR-15-0110] [PMID: 26968206]
[26]
Ni, W.; Zhang, S.; Jiang, B.; Ni, R.; Xiao, M.; Lu, C.; Liu, J.; Qu, L.; Ni, H.; Zhang, W.; Zhou, P. Identification of cancer-related gene network in hepatocellular carcinoma by combined bioinformatic approach and experimental validation. Pathol. Res. Pract., 2019, 215(6)152428 Epub ahead of print
[http://dx.doi.org/10.1016/j.prp.2019.04.020] [PMID: 31064721]
[27]
European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 2012, 56(4), 908-943.
[http://dx.doi.org/10.1016/j.jhep.2011.12.001] [PMID: 22424438]
[28]
Child, C.G.; Turcotte, J.G. Surgery and portal hypertension. Major Probl. Clin. Surg., 1964, 1, 1-85.
[PMID: 4950264]
[29]
Kamath, P.S.; Wiesner, R.H.; Malinchoc, M.; Kremers, W.; Therneau, T.M.; Kosberg, C.L.; D’Amico, G.; Dickson, E.R.; Kim, W.R. A model to predict survival in patients with end-stage liver disease. Hepatology, 2001, 33(2), 464-470.
[http://dx.doi.org/10.1053/jhep.2001.22172] [PMID: 11172350]
[30]
Johnson, P.J.; Berhane, S.; Kagebayashi, C.; Satomura, S.; Teng, M.; Reeves, H.L.; O’Beirne, J.; Fox, R.; Skowronska, A.; Palmer, D.; Yeo, W.; Mo, F.; Lai, P.; Iñarrairaegui, M.; Chan, S.L.; Sangro, B.; Miksad, R.; Tada, T.; Kumada, T.; Toyoda, H. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade. J. Clin. Oncol., 2015, 33(6), 550-558.
[http://dx.doi.org/10.1200/JCO.2014.57.9151] [PMID: 25512453]
[31]
Llovet, J.M.; Brú, C.; Bruix, J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis., 1999, 19(3), 329-338.
[http://dx.doi.org/10.1055/s-2007-1007122] [PMID: 10518312]
[32]
Hanley, J.A.; McNeil, B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 1982, 143(1), 29-36.
[http://dx.doi.org/10.1148/radiology.143.1.7063747] [PMID: 7063747]
[33]
Esmat, G.; El Kassas, M.; Elbaz, T. Hepatocellular carcinoma in Egypt: An updated status, worldwide digestive health day (WDHD); Liver Cancer Act Today, 2013.
[34]
Aravalli, R.N. Development of micro RNA therapeutics for hepatocellular carcinoma. Diagnostics (Basel), 2013, 3(1), 170-191.
[http://dx.doi.org/10.3390/diagnostics3010170] [PMID: 26835673]
[35]
Lee, S.K.; Song, M.J.; Kim, S.H.; Park, M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS One, 2019, 14(5)e0216173
[http://dx.doi.org/10.1371/journal.pone.0216173] [PMID: 31048923]
[36]
Hiraoka, A.; Kumada, T.; Tsuji, K.; Takaguchi, K.; Itobayashi, E.; Kariyama, K.; Ochi, H.; Tajiri, K.; Hirooka, M.; Shimada, N.; Ishikawa, T.; Tachi, Y.; Tada, T.; Toyoda, H.; Nouso, K.; Joko, K.; Hiasa, Y.; Michitaka, K.; Kudo, M. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: A multicenter analysis. Liver Cancer, 2019, 8(2), 121-129.
[http://dx.doi.org/10.1159/000488778] [PMID: 31019902]
[37]
Shimose, S.; Tanaka, M.; Iwamoto, H.; Niizeki, T.; Shirono, T.; Aino, H.; Noda, Y.; Kamachi, N.; Okamura, S.; Nakano, M.; Kuromatsu, R.; Kawaguchi, T.; Kawaguchi, A.; Koga, H.; Yokokura, Y.; Torimura, T. Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatol. Res., 2019. Epub ahead of print
[http://dx.doi.org/10.1111/hepr.13348] [PMID: 30969006]
[38]
Pardoll, D.; Drake, C. Immunotherapy earns its spot in the ranks of cancer therapy. J. Exp. Med., 2012, 209(2), 201-209.
[http://dx.doi.org/10.1084/jem.20112275] [PMID: 22330682]
[39]
Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; Larkin, J.; Lorigan, P.; Neyns, B.; Blank, C.U.; Hamid, O.; Mateus, C.; Shapira-Frommer, R.; Kosh, M.; Zhou, H.; Ibrahim, N.; Ebbinghaus, S.; Ribas, A. KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med., 2015, 372(26), 2521-2532.
[http://dx.doi.org/10.1056/NEJMoa1503093] [PMID: 25891173]
[40]
Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; Carcereny, E.; Ahn, M.J.; Felip, E.; Lee, J.S.; Hellmann, M.D.; Hamid, O.; Goldman, J.W.; Soria, J.C.; Dolled-Filhart, M.; Rutledge, R.Z.; Zhang, J.; Lunceford, J.K.; Rangwala, R.; Lubiniecki, G.M.; Roach, C.; Emancipator, K.; Gandhi, L. KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med., 2015, 372(21), 2018-2028.
[http://dx.doi.org/10.1056/NEJMoa1501824] [PMID: 25891174]
[41]
El-Khoueiry, A.; Melero, I.; Crocenzi, T.S.; Welling, T.H.; Yau, T.C.; Chopra, W.Y.; Grosso, J.; Lang, L.; Anderson, J.; Cruz, C.M.D.; Sangro, B. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209e040. American Society of Clinical Oncology (ASCO Annual Meeting, 2015.Chicago
[42]
Kew, M. Hepatic tumors and cysts.Gastrointestinal and liver disease; (6th ed. ). , 2002. 2007-2020.
[43]
Lok, A.S.; Sterling, R.K.; Everhart, J.E.; Wright, E.C.; Hoefs, J.C.; Di Bisceglie, A.M.; Morgan, T.R.; Kim, H.Y.; Lee, W.M.; Bonkovsky, H.L.; Dienstag, J.L. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology, 2010, 138(2), 493-502.
[http://dx.doi.org/10.1053/j.gastro.2009.10.031] [PMID: 19852963]
[44]
Kim, H.J.; Park, S.; Kim, K.J.; Seong, J. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother. Oncol., 2018, 129(1), 130-135.
[http://dx.doi.org/10.1016/j.radonc.2017.11.027] [PMID: 29366520]
[45]
Finkelmeier, F.; Canli, Ö.; Tal, A.; Pleli, T.; Trojan, J.; Schmidt, M.; Kronenberger, B.; Zeuzem, S.; Piiper, A.; Greten, F.R.; Waidmann, O. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur. J. Cancer, 2016, 59, 152-159.
[http://dx.doi.org/10.1016/j.ejca.2016.03.002] [PMID: 27039170]
[46]
Yamagiwa, S.; Ishikawa, T.; Waguri, N.; Sugitani, S.; Kamimura, K.; Tsuchiya, A.; Takamura, M.; Kawai, H.; Terai, S. Terai1, S. Increase of soluble programmed cell death ligand 1 in patients with Chronic Hepatitis C. Int. J. Med. Sci., 2017, 14(5), 403-411.
[http://dx.doi.org/10.7150/ijms.18784] [PMID: 28539815]
[47]
Gu, X.; Gao, X.S.; Xiong, W.; Guo, W.; Han, L.; Bai, Y.; Peng, C.; Cui, M.; Xie, M. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. OncoTargets Ther., 2016, 9, 4805-4813.
[http://dx.doi.org/10.2147/OTT.S110713] [PMID: 27536144]
[48]
Rossille, D.; Gressier, M.; Damotte, D.; Maucort-Boulch, D.; Pangault, C.; Semana, G.; Le Gouill, S.; Haioun, C.; Tarte, K.; Lamy, T.; Milpied, N.; Fest, T. Groupe Ouest-Est des Leucémies et Autres Maladies du Sang; Groupe Ouest-Est des Leucémies et Autres Maladies du Sang. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: Results from a French multicenter clinical trial. Leukemia, 2014, 28(12), 2367-2375.
[http://dx.doi.org/10.1038/leu.2014.137] [PMID: 24732592]


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 11
Year: 2019
Page: [896 - 905]
Pages: 10
DOI: 10.2174/1568009619666190718141647
Price: $65

Article Metrics

PDF: 35
HTML: 1